* For FY 2025, Sphera reported a net profit of RON 57.6m, down 40.8% Y/Y as inflationary cost pressures weighed on largely stable sales. The bottom line came RON 8.8m above our estimate of RON 48.8m, mainly supported by RON …
File Type: pdf
* For FY 2025, MedLife booked a net loss of RON 4m versus a net profit of RON 16.4m in FY 2024, as FX losses from the revaluation of FX-denominated debt surged to RON 46.2m compared with RON 1.3m a …
* For FY 2025, Romgaz posted a consolidated IFRS net profit of RON 3,347m, up 5% Y/Y and 2.4% above our RON 3,269m forecast mainly on lower-than-expected income tax, which ended 23% below our estimate and resulted in an effective tax …
* TTS reported a net loss attributable to shareholders of RON 12m in 2025, compared to a profit of RON 19m in 2024 and versus our estimate of a RON 7m loss, as the company faced a challenging operating environment across …
* For FY 2025, Antibiotice delivered a clear profitability reset versus 2024 despite broadly stable activity. Operating income declined 2% Y/Y, with turnover down 4% Y/Y to RON 645.3m, while total operating expenses increased 4% Y/Y to RON 599.7m. This …
